WuXi PharmaTech Provides Update of 2012 Financial Guidance, to Present at J.P. Morgan Healthcare Conference

SHANGHAI,  Jan. 7, 2013 -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development services company, with operations in  China  and  the United States, today
announced that it will present at the 31th Annual J.P. Morgan Healthcare Conference on  Wednesday, January 9, 2013  at  8:30 a.m. Pacific Standard Time and updated its 2012 financial guidance. Based on preliminary, unaudited results, WuXi expects to achieve total revenues of approximately  $500 million and to meet the remainder of the 2012 financial guidance found in its third-quarter 2012 earnings release. 

WuXi plans to report its audited fourth-quarter and full-year 2012 financial results and to provide 2013 financial guidance in  March 2013.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.